Castleark Management LLC Spring Works Therapeutics, Inc. Transaction History

Castleark Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$36.06 - $47.62 $966,768 - $1.28 Million	26,810 Added 34.22%	105,160 $3.96 Million
Q1 2024 May 15, 2024	BUY	$36.5 - $52.5 $193,450 - $278,250	5,300 Added 7.26%	78,350 $3.86 Million
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $1.38 Million - $2.72 Million	73,050 New	73,050 $2.67 Million
Q4 2021 Feb 16, 2022	SELL	$53.3 - $75.84 $4.75 Million - $6.76 Million	-89,086 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$62.66 - $88.26 $162,916 - $229,476	-2,600 Reduced 2.84%	89,086 $5.65 Million
Q2 2021 Aug 17, 2021	SELL	$67.45 - $85.63 $153,111 - $194,380	-2,270 Reduced 2.42%	91,686 $7.56 Million
Q1 2021 May 14, 2021	BUY	$65.1 - $93.59 $1.19 Million - $1.71 Million	18,300 Added 24.19%	93,956 $6.91 Million
Q4 2020 Feb 17, 2021	BUY	$48.36 - $77.92 $3.66 Million - $5.9 Million	75,656 New	75,656 $5.49 Million

237

68.9M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.22B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.